"Personalized medicine: elusive dream or imminent reality?": A commentary.
I was invited to comment on the article in this issue by Larry Lesko, "Personalized Medicine: Elusive Dream or Imminent Reality?",(1) especially with respect to three questions. There are several possible approaches to discussing these questions. One is to simply answer the question as directly and succinctly as possible; another is to expand on the questions. For the purpose of this Commentary, I try to do both.
Roses
A
A
Genetics Research and Development, GlaxoSmithKline, Research Triangle Park, North Carolina, USA. allen.d.roses@gsk.com
D019380:Anti-HIV Agents / Q000009:adverse effects / Q000627:therapeutic use; D035843:Biomedical Research / Q000379:methods*; D015224:Dideoxynucleosides / Q000009:adverse effects / Q000627:therapeutic use; D004345:Drug Industry / Q000191:economics / Q000592:standards*; D064420:Drug-Related Side Effects and Adverse Reactions; D006801:Humans; D025202:Molecular Diagnostic Techniques; D004364:Pharmaceutical Preparations / Q000008:administration & dosage*; D010597:Pharmacogenetics; D011358:Product Surveillance, Postmarketing; D011446:Prospective Studies; D016032:Randomized Controlled Trials as Topic; D000099227:Abacavir
D019380:Anti-HIV Agents; D015224:Dideoxynucleosides; D004364:Pharmaceutical Preparations; D000099227:Abacavir